Elena Molokanova
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2017First federal award
$6.6MFederal grants as PI13 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
13 awards · $6.6M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Apr 4, 2025 | NIH | SBIR Phase II Evaluation of the therapeutic potential of exclusive antagonists of extrasynaptic NMDA receptors for the treatment of opioid use disorder | $811K | NEURANO BIOSCIENCE LLC |
| Apr 23, 2024 | NIH | SBIR Phase II Evaluation of the therapeutic potential of exclusive antagonists of extrasynaptic NMDA receptors for the treatment of opioid use disorder | $838K | NEURANO BIOSCIENCE LLC |
| May 15, 2023 | NIH | SBIR Phase II Evaluation of the therapeutic potential of exclusive antagonists of extrasynaptic NMDA receptors for the treatment of opioid use disorder | $836K | NEURANO BIOSCIENCE LLC |
| May 5, 2023 | NIH | SBIR Phase II Evaluation of the therapeutic potential of exclusive antagonists of extrasynaptic NMDA receptors for the treatment of opioid use disorder | $836K | NEURANO BIOSCIENCE LLC |
| Apr 29, 2022 | NIH | SBIR Phase I Alzheimer's disease and novel nanotherapeutics exclusively targeting extrasynaptic NMDA receptors | $57K | NEURANO BIOSCIENCE LLC |
| Sep 30, 2021 | NIH | SBIR Phase I Alzheimer's disease and novel nanotherapeuticsexclusively targeting extrasynaptic NMDA receptors | $557K | NEURANO BIOSCIENCE LLC |
| Sep 21, 2021 | NIH | SBIR Phase I Alzheimer's disease and novel nanotherapeutics exclusively targeting extrasynaptic NMDA receptors | $500K | NEURANO BIOSCIENCE LLC |
| Sep 1, 2021 | NIH | SBIR Phase I Pre-clinical evaluation of a rationally designed nanotherapeutic for Huntington's disease | $519K | NEURANO BIOSCIENCE LLC |
| Aug 30, 2021 | NIH | SBIR Phase I Pre-Clinical Evaluation of a Rationally Designed Nanotherapeutic for Huntington's Disease | $519K | NEURANO BIOSCIENCE LLC |
| Sep 17, 2019 | NIH | SBIR Phase I Evaluation of the therapeutic potential of exclusive antagonists of extrasynaptic NMDA receptors for treatment of opioid use disorders | $350K | NEURANO BIOSCIENCE LLC |
| 2018 | NSF | SBIR Phase I SBIR Phase I: Optoelectronic Microplates: Disruptive Optical Stimulation Technology for Drug Discovery Screening Assays | $225K | Nanotools Bioscience |
| Dec 19, 2017 | NSF | SBIR Phase I SBIR Phase I: Optoelectronic Microplates: Disruptive Optical Stimulation Technology for Drug Discovery Screening Assays | $225K | Nanotools Bioscience |
| Sep 1, 2017 | NIH | SBIR Phase I Novel nanotechnology based optical stimulation platform for predictive cardiotoxicity assessment | $325K | Nanotools Bioscience |
Peer ranks
Federal funding#157
Awards as PI#72
Patents#273
Companies
- Nanotools BioscienceLinked by awards · Biotech
- NEURANO BIOSCIENCE LLCLinked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.